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Abstract Background: Previous studies have shown disparities between Black and
Hispanic patients compared with other populations in response to asthma
medications.
Objective: The aim of this analysis was to assess the effect of budesonide/
formoterol pressurized metered-dose inhaler (BUD/FM pMDI) and BUD on
predefined criteria for asthma worsening, an asthma control metric generally
aligned with definitions of moderate asthma exacerbations, across four dif-
ferent populations.
Methods:Datawere from four 12-week, randomized, double-blind,US studies of
BUD/FM pMDI treatment in patients aged 12 years or older with varying
asthma severities and of varying races. Predefined asthma events and with-
drawals due to predefined events were assessed as secondary study endpoints.
Study I (NCT00651651) includes data from predominantly White patients
with mild to moderate asthma who were randomized to BUD/FM pMDI
160/9mg twice daily (bid; n= 123) or BUDpMDI 160mg bid (n= 121). Study II
(NCT00652002) includes data from predominantlyWhite patients withmoderate
to severe asthma who were randomized to BUD/FM pMDI 320/9mg bid
(n= 124) or BUD pMDI 320mg bid (n = 109). Study III (NCT00702325) in-
cluded self-reported Black patients with moderate to severe asthma who were
randomized to BUD/FM pMDI 320/9mg bid (n = 153) or BUD dry powder
inhaler 360mg bid (n = 148). Study IV (NCT00419757) included self-reported
Hispanic patients with moderate to severe asthma who were randomized to
BUD/FM pMDI 320/9 mg bid (n= 127) or BUD pMDI 320mg bid (n= 123).
Patients were to be withdrawn from the studies if they developed an asthma
event, as determined by predefined criteria, except for night-time awakenings,
where withdrawal was left to the study physician’s judgment.
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Results: Overall, fewer patients in the studies (study I, II, III, and IV, re-
spectively) experienced ‡1 asthma event in the BUD/FM group (18.7%,
29.8%, 37.3%, 25.2%) versus the BUD group (21.5%, 44.0%, 45.3%, 31.7%);
only study II results showed a statistically significant difference between
treatments. Fewer patients with moderate to severe asthma (studies II, III,
and IV) were withdrawn due to ‡1 asthma event in the BUD/FM group
(10.5%, 11.8%, 3.1%, respectively) than in the BUD group (20.2%, 18.9%,
6.5%, respectively); however, percentages were similar in the BUD/FM (7.3%)
and BUD (6.6%) groups in patients with mild to moderate asthma (study I).
Conclusions: Predefined asthma event rates were numerically or significantly
lower for patientswith asthma receivingBUD/FMpMDI versus BUD, regardless
of race or disease severity. Differences between the BUD/FM pMDI and BUD
groups were smaller in patients with mild to moderate asthma than in those with
moderate to severe asthma, most likely because patients with milder disease had
lower asthma event rates. Overall, these findings support the efficacy of BUD/FM
pMDI in achieving asthma control in patients with moderate to severe asthma.
Introduction
Asthma disproportionately affects racial and
ethnic populations. In the US in 2006, the age-
adjusted, asthma-related mortality rates were ap-
proximately 3 times higher in non-Hispanic Blacks
than in non-Hispanic Whites and Hispanics.[1] Al-
though typical safety and efficacy studies are under-
powered or too short in duration to make definitive
conclusions regarding severe asthma exacerbations
(i.e. those requiring systemic corticosteroids),
important insight into the efficacy of medications
can be gained from analyzing related moderate
exacerbation events characterized by a sustained
loss of asthma control (beyond normal day-to-
day variation) that does not meet the definition
of a severe exacerbation.[2] For the purpose of
asthma research protocol development, moderate
exacerbation events have been captured using vari-
ous terminology, such as asthma deterioration,[3]
asthma worsenings,[4] and asthma events.[5] Few
US studies have evaluated the safety and efficacy
of an inhaled corticosteroid (ICS)/long-acting b2-
adrenergic agonist (LABA) combination therapy
in Black or Hispanic patients with asthma. The
efficacy of budesonide/formoterol (BUD/FM) pres-
surized metered-dose inhaler (pMDI) has been
evaluated in randomized, double-blind studies in
predominantly White patients with mild to mod-
erate asthma[6] and predominantlyWhite,[5] Black,[7]
and Hispanic[8] patients with moderate to severe
asthma. Results for a predefined asthma event
definition, which encompass moderate to severe
asthma deteriorations, are presented as these
findings have not been presented previously in
detail or compared across patient populations.
Methods
Table I includes a brief summary of the studies
that were included in this exploratory analysis.
Additional details of the individual studies, in-
cluding study design and methods, have been
previously described.[5-8] This analysis of predefined
asthma events (table II) includes data from patients
aged ‡12 years with asthma who were enrolled in
randomized, double-blind, 12-week US studies
that differed according to baseline asthma se-
verity and/or race or ethnicity (table III). Only
the BUD/FM and BUD treatment arms, which
were common to all four studies, are presented;
these studies were not originally powered for
comparison of asthma events.
Statistical methods for this analysis are similar
to those described previously.[5-8] Comparisons
among treatment groups of percentages of patients
10 Murphy et al.
ª 2012 Murphy et al., publisher and licensee Adis Data Information BV. Drugs R D 2012; 12 (1)
who experienced ‡1 predefined asthma event and of
percentages of patients who withdrew because of
such an event were performed by w2 test (study I) or
Cochran-Mantel-Haenszel test with adjustment for
treatment (studies III and IV) and ICS dose (me-
dium or high; studies II, III, and IV) at study entry.
Results
Baseline demographics were similar across
studies (table II). As expected, patients with mild
to moderate asthma had better pulmonary func-
tion than those with moderate to severe asthma.
The percentage of patients with moderate to
severe asthma who experienced ‡1 asthma event
was lower in the BUD/FM groups versus the
BUD group, with statistically significant differ-
ences observed in study II (p < 0.05) [figure 1]. In
all studies, the most commonly met predefined
criterion was night-time awakening. The pre-
defined criterion of clinical exacerbation included
the following subcategories that were not mu-
tually exclusive:
 study I (BUD/FM: one patient [one emergency
department (ED) visit, one event of disallowed
asthma medication use], BUD: three patients
[one ED visit, three events of disallowed asthma
medication use]);
 study II (BUD/FM: seven patients [three ED
visits, seven events of disallowed asthma
medication use], BUD: five patients [one ED
visit, four events of disallowed asthmamedica-
tion use]);
 study III (BUD/FM: three patients [two events
of disallowed asthma medication use, one
event of nebulized bronchodilator use, three
events of oral corticosteroid use], BUD: three
patients [one ED visit, three events of disal-
lowed asthma medication use, one event of
nebulized bronchodilator use, and three events
of oral corticosteroid use]);
 study IV (BUD/FM: seven patients [two ED
visits, two hospitalizations – one due to multiple
Table I. Study treatments and entry criteria[5-8]
Study Run-in Interventions Race Asthma severity
I (NCT00651651)[6] Placebo pMDI bid BUD/FM pMDI 160/9 mg (n =123)
BUD pMDI 160mg (n= 121)
FM DPI 9 mg (n =114)
Placebo (n =122)
Not specified Mild to moderate
II (NCT00652002)[5] BUD pMDI 160 mg bid BUD/FM pMDI 320/9 mg (n =124)
BUD pMDI 320mg (n= 109)
BUD pMDI 320mg +FM DPI 9mg (n = 115)
FM DPI 9 mg (n =123)
Placebo (n =125)
Not specified Moderate to severe
III (NCT00702325)[7] BUD DPI 180mg bid BUD/FM pMDI 320/9 mg (n =156)
BUD DPI 360 mg (n =155)
Self-reported Blacka Moderate to severe
IV (NCT00419757)[8] BUD pMDI 160 mg bid BUD/FM pMDI 320/9 mg (n =127)
BUD pMDI 320mg (n= 123)
Self-reported Hispanicb Moderate to severe
a Self-reported as African, African American, or African Caribbean.
b Self-reported as Mexican, Puerto Rican, Cuban, South or Central American, Caribbean, or mixed Hispanic.
bid = twice daily; BUD =budesonide; DPI= dry powder inhaler; FM = formoterol; pMDI = pressurized metered-dose inhaler.
Table II. Predefined criteria for asthma events[5-8]
1. Decrease in morning predose FEV1 ‡20% from randomization or a
decrease to <40%a of predicted normal
2. ‡12 Actuations of albuterol/day on ‡3 days within a 7-day period
3. Decrease in morning PEF ‡20% from baseline on ‡3 days within a
7-day period
4. ‡2 Nights with an awakening due to asthma requiring rescue
medication within any 7-day periodb
5. Clinical exacerbation requiring emergency treatment,
hospitalization, or use of an asthma medication not allowed by the
protocol
a For study I, <45%.
b Patients experiencing only the night-time awakening criterion
could remain in the study if the investigator determined that they
were clinically well and stable.
FEV1= forced expiratory volume in 1 second; PEF = peak expiratory
flow.
BUD/FM pMDI and Asthma Events in Four Populations 11
ª 2012 Murphy et al., publisher and licensee Adis Data Information BV. Drugs R D 2012; 12 (1)
significant/active comorbidities and one due to
viral infection, seven events of disallowed
asthma medication use], BUD: two patients
[two events of disallowed medication use]).
Overall, withdrawal rates were lower in studies
I and IV than in studies II and III (figure 1). The
percentage of patients with mild to moderate
asthma (study I) whowithdrew due to ‡1 predefined
asthma event was similar in the BUD/FM and
BUD groups. Percentages of patients with moder-
ate to severe asthma (studies II, III, and IV) who
withdrew due to ‡1 asthma event were numerically
lower in the BUD/FM versus BUD groups, re-
gardless of race. Additional results from the in-
dividual studies have been previously described.[5-8]
Conclusions
Predefined asthma events are increasingly
being utilized in clinical research studies as a sen-
sitive composite control metric. An asthma event
metric encompassing measures of pulmonary
function, symptoms, rescue medication use, and
the need for additional medications was inves-
tigated in the present analysis. While individual
studies were not powered for statistical analyses,
predefined asthma event rates in four 12-week,
randomized studies consistently showed numerical
or significant differences favoring BUD/FM pMDI
over BUD across White, Black, and Hispanic
patients, regardless of disease severity. Notably,
the results of this analysis showing similar pre-
defined asthma event rates among patients of dif-
fering racial backgrounds is consistent with the
primary analyses showing the efficacy of BUD/
FMpMDI in Blacks[7] and Hispanics,[8] as well as
a study demonstrating the efficacy of ICS/LABA
in Blacks.[9] Additional discussion of findings and
limitations of the individual studies have been
previously discussed.[5-8] Differences between the
BUD/FM pMDI and BUD groups were smaller
in patients with mild to moderate asthma than in
patients with moderate to severe asthma, most
likely because patients with milder disease had
overall lower asthma event rates. These data fur-
ther support the efficacy of BUD/FM pMDI in
achieving asthma control in patients with mod-
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